Medical spas and aesthetic practices are increasingly expanding beyond traditional offerings into wellness, longevity, and regenerative medicine, including GLP-1 weight-loss programs, IV infusion therapy, and hormone optimization. While these services present exciting opportunities, they also introduce distinct legal and regulatory considerations that practice owners should evaluate carefully before expanding their scope of services.
In an article in The Aesthetic Guide, Brandon Zarsky examines key issues for practices adding these services. He explains that scope of practice and physician oversight rules vary by state, and that owners should confirm which licensed professionals may order, administer, and supervise therapies such as hormone replacement and peptides. Brandon also highlights the risks of compounded products, including the need to source from licensed, compliant pharmacies and the regulatory scrutiny of “research use only” peptides. He further addresses advertising claims, particularly comparisons between compounded GLP-1 drugs and branded products, and the importance of confirming that professional liability and malpractice policies actually cover these new services.
